ReShape Lifesciences (RSLS)

Company Profile

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.

Company profile

Ticker

RSLS

Exchange

NASDAQ

Website

www.reshapelifesciences.com

CEO

Andrew Rasdal

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • West Pharmaceutical Services • Haemonetics • Hill-Rom ...

Former names

OBALON THERAPEUTICS INC

SEC CIK

0001427570

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

ReShape Weightloss, Inc. • ReShape Lifesciences Netherlands B.V. • ReShape Lifesciences Australia Pty Ltd • ReShape Costa Rica Sociedad de Responsabilidad Limited • Obalon Center for Weight Loss, Inc. ...

RSLS stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

ReShape Lifesciences Announces Pricing of Upsized

10 Feb 23

424B4

Prospectus supplement with pricing info

8 Feb 23

EFFECT

Notice of effectiveness

6 Feb 23

S-1MEF

Registration of additional securities for an S-1

3 Feb 23

S-1/A

IPO registration (amended)

3 Feb 23

CORRESP

Correspondence with SEC

3 Feb 23

CORRESP

Correspondence with SEC

3 Feb 23

RW WD

Withdrawal of registration withdrawal request

2 Feb 23

Registration withdrawal request

2 Feb 23

Registration withdrawal request

2 Feb 23

Transcripts

View all

RSLS

Earnings call transcript

2022 Q3

14 Nov 22

RSLS

Earnings call transcript

2022 Q2

16 Aug 22

RSLS

Earnings call transcript

2019 Q4

29 Feb 20

RSLS

Earnings call transcript

2019 Q3

8 Nov 19

RSLS

Earnings call transcript

2019 Q2

24 Jul 19

RSLS

Earnings call transcript

2018 Q4

22 Feb 19

RSLS

Earnings call transcript

2018 Q3

2 Nov 18

RSLS

Earnings call transcript

2018 Q2

4 Aug 18

RSLS

Earnings call transcript

2018 Q1

12 May 18

RSLS

Earnings call transcript

2017 Q4

6 Mar 18

Latest ownership filings

View all

SC 13D

Matthew Joseph Nachtrab Revocable Trust 2014

ARMISTICE CAPITAL, LLC

Financial summary

Financial statements Chart RSLS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.25 mm	6.25 mm	6.25 mm	6.25 mm	6.25 mm	6.25 mm
Cash burn (monthly)	1.77 mm	1.92 mm	4.06 mm	5.48 mm	1.76 mm	1.87 mm
Cash used (since last report)	10.09 mm	10.97 mm	23.18 mm	31.29 mm	10.04 mm	10.71 mm
Cash remaining	-3.84 mm	-4.73 mm	-16.94 mm	-25.05 mm	-3.79 mm	-4.47 mm
Runway (months of cash)	-2.2	-2.5	-4.2	-4.6	-2.2	-2.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

RSLS institutional ownership history Ownership history

18.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	13	23	-43.5%
Opened positions	3	5	-40.0%
Closed positions	13	3	+333.3%
Increased positions	0	4	EXIT
Reduced positions	8	6	+33.3%

13F shares	Current	Prev Q	Change
Total value	2.21 mm	226.00 k	+879.2%
Total shares	95.83 k	791.35 k	-87.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Domain Parters Vii L P	62.50 k	$0.00	0.0%
Armistice Capital	25.40 k	$0.00	NEW
Interwest Partners X	6.25 k	$10.00 k	0.0%
Tower Research Capital	1.36 k	$9.00 k	-95.8%
UBS UBS Group AG - Registered Shares	264.00	$1.78 mm	-79.5%
Cornerstone Planning	35.00	$252.00 k	NEW
BLK Blackrock	17.00	$115.00 k	-98.1%
Advisor	5.00	$0.00	-99.9%
WFC Wells Fargo & Co.	3.00	$20.00 k	-98.0%
Group One Trading	3.00	$20.00 k	-97.3%

Largest transactions	Shares	Bought/sold	Change
Geode Capital Management	0.00	-306.61 k	EXIT
Vanguard	0.00	-118.61 k	EXIT
HRT Financial	0.00	-55.89 k	EXIT
T. Rowe Price	0.00	-36.10 k	EXIT
NTRS Northern Trust	0.00	-33.43 k	EXIT
Renaissance Technologies	0.00	-32.88 k	EXIT
Tower Research Capital	1.36 k	-30.88 k	-95.8%
Susquehanna Fundamental Investments	0.00	-30.20 k	EXIT
Armistice Capital	25.40 k	+25.40 k	NEW
Two Sigma Securities	0.00	-20.29 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RSLS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Feb 23	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	4.25	103	437.75	6,091
2 Feb 23	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	13.29	157	2.09 k	6,194
24 Jan 23	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	7.4906	110	823.97	6,351
24 Jan 23	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	7.49	48	359.52	6,461
1 Dec 22	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	0.1509	2,213	333.94	325,404
1 Dec 22	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	0.1513	5,144	778.29	327,617
28 Nov 22	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	0.1695	364,756	61.83 k	332,761
17 Nov 22	Thomas Stankovich	Common Stock, $0.001 par value per share	Grant	Acquire A	No	No	0	364,756	0.00	697,517
4 Nov 22	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	0.2724	2,510	683.72	332,761
4 Nov 22	Thomas Stankovich	Common Stock, $0.001 par value per share	Sell	Dispose S	No	No	0.2725	5,883	1.60 k	335,271